Latest news
The Recruiter in the Frame: What a Danish RSV Trial Reveals About Who Gets to Invite You Into a Study - The Clinical Trial VanguardThe Clinical Trial Vanguard · Mon, 03 Aug 2026 07:38:08 GMTMesoblast’s Ryoncil Posts $115M First-Year Revenue on Pediatric Approval - The Clinical Trial VanguardThe Clinical Trial Vanguard · Mon, 03 Aug 2026 06:38:08 GMTWave Life Sciences Advances WVE-007 to Phase 2a for Obesity and Metabolic Disease - The Clinical Trial VanguardThe Clinical Trial Vanguard · Mon, 03 Aug 2026 06:38:08 GMTMesoblast Posts US$115m First-Year Ryoncil Sales and Advances Late-Stage Cell Therapy Pipeline - TipRanksTipRanks · Thu, 30 Jul 2026 12:54:25 GMTMesoblast posts $36M Ryoncil revenue in Q4, holds $103M cash - scanx.tradescanx.trade · Thu, 30 Jul 2026 07:00:00 GMTMesoblast (ASX:MSB) Is Back in Focus After RYONCIL Revenue Reaches US$115 Million - KalkineKalkine · Thu, 30 Jul 2026 07:00:00 GMTMesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 01:15:08 GMTMesoblast reports $115M Ryoncil revenue in firs... - PluangPluang · Thu, 30 Jul 2026 01:11:43 GMT